{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:06:38Z","timestamp":1784700398029,"version":"3.55.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Concurrent chemoradiotherapy (cCRT) remains the standard treatment for patients diagnosed with limited-stage small-cell lung cancer (LS-SCLC); however, recurrence rates remain high and prognosis remains poor. This study collected data regarding patient-reported outcomes and adverse events (AEs) to evaluate the effects of chemoradiotherapy combined with immunotherapy in patients with LS-SCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search of 7 electronic databases was conducted for randomized, placebo-controlled trials enrolling patients diagnosed with LS-SCLC who received chemoradiotherapy combined with immunotherapy. Trials with unstratified LS-SCLC samples were excluded. A subsequent meta-analysis was performed. This study was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under accession number CRD42024607159.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine trials comprising 1,853 patients were included. CCRT combined with immunotherapy exhibited a significant favorable trend in survival outcomes, with hazard ratios (HRs) for median progression-free survival (mPFS) and median overall survival (mOS) of\n                      <jats:italic>0.838<\/jats:italic>\n                      (95% confidence interval [CI]: 0.742\u20130.947) and 0.847 (95% CI: 0.736\u20130.975), especially in the consolidation group with HRs for mPFS and mOS of 0.793 (95% CI: 0.675\u20130.930) and 0.757 (95% CI: 0.551\u20131.040), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CCRT combined with immunotherapy improved survival in patients with LS-SCLC, especially in the consolidation immunotherapy group. The treatment regimen was generally well tolerated, with an acceptable incidence of treatment-related adverse events (TRAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD42024607159.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1731036","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:53:19Z","timestamp":1784699599000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of immunotherapy combined with chemoradiotherapy in limited-stage small cell lung cancer: a systematic evaluation and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Yixuan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Thoracic Radiation Oncology, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Liu","sequence":"additional","affiliation":[{"name":"College of Bioinformatics Science and Technology, Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiang\u2019an Hospital of Xiamen University","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Radiation Oncology, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishuang","family":"Qi","sequence":"additional","affiliation":[{"name":"College of Bioinformatics Science and Technology, Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Radiation Oncology, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8129","DOI":"10.3390\/ijms24098129","article-title":"Small-cell lung cancer\u2014an update on targeted and immunotherapies","volume":"24","author":"McNamee","year":"2023"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21785","article-title":"Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA: A Cancer J For Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz264","article-title":"1736O - IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)","volume":"30","author":"Reck","year":"2019","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S1562","DOI":"10.1016\/j.annonc.2022.10.351","article-title":"LBA9 updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: an international multicentre phase III study (ASTRUM-005)","volume":"33","author":"Cheng","year":"2022","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol Off Publ Int Assoc For Study Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5","article-title":"ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)","volume":"42","author":"Spigel","year":"2024","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.963","article-title":"P3.13.27 toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study","volume":"20","author":"Zhang","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8005","article-title":"Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC)","volume":"43","author":"Gronberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41392-025-02445-y","article-title":"Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","article-title":"Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP\/IFCT 4-12 STIMULI trial","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2022.03.034","article-title":"Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer","volume":"169","author":"Park","year":"2022","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-01569","article-title":"Chemoradiation \u00b1 atezolizumab in limited-stage small cell lung cancer: results of NRG Oncology\/Alliance LU005","volume":"44","author":"Higgins","year":"2026","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S615","DOI":"10.1016\/j.jtho.2025.09.1161","article-title":"PT2.13.01 a phase II trial of induction camrelizumab plus chemotherapy followed by chemoradiotherapy and consolidation in limited-stage SCLC","volume":"20","author":"Liu","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100911","article-title":"AdvanTIG-204: a phase 2, randomized, open-label study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy versus tislelizumab and concurrent chemotherapy versus concurrent chemoradiotherapy in first-line limited-stage SCLC","volume":"6","author":"Gong","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157164","article-title":"Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy","volume":"11","author":"Young","year":"2016","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13073-019-0653-7","article-title":"Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system","volume":"11","author":"Lhuillier","year":"2019","journal-title":"Genome Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2102611118","DOI":"10.1073\/pnas.2102611118","article-title":"Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads","volume":"118","author":"Lussier","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03154","article-title":"Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment","volume":"9","author":"Darragh","year":"2018","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00903-x","article-title":"Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy","volume":"26","author":"Darragh","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"eabg0117","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-025-02781-8","article-title":"Meta-analysis of 5-year survival data for cancers without considering time is misleading","volume":"14","author":"Mohammadi","year":"2025","journal-title":"Systematic Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108840","article-title":"Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)","volume":"210","author":"Phillips","year":"2025","journal-title":"Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"40167","DOI":"10.1038\/s41598-025-23874-3","article-title":"Comparison of efficacy and safety of first-line immunotherapy combined with chemotherapy in extensive-stage small cell lung cancer, a retrospective study","volume":"15","author":"Dong","year":"2025","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100669","article-title":"Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: a comprehensive reanalysis of randomized controlled trials","volume":"6","author":"Zhang","year":"2025","journal-title":"Med (New York NY)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13045-018-0584-6","article-title":"The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma","volume":"11","author":"Shi","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8579","article-title":"CheckMate 451: a randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC)","volume":"34","author":"Ready","year":"2016"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100884","article-title":"Durvalumab with or without tremelimumab in combination with chemoradiotherapy in patients with limited-stage SCLC: results from the phase 1 CLOVER study","volume":"6","author":"Cho","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2023.100596","article-title":"Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy","volume":"3","author":"Zhao","year":"2023","journal-title":"Cell Rep Methods"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251363518","article-title":"State of the art in treatment of small cell lung cancer","volume":"17","author":"Behrouzi","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01359","article-title":"High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538","volume":"41","author":"Bogart","year":"2023","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.02.063","article-title":"Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: a brief report from the CONVERT trial","volume":"119","author":"Walls","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.021","article-title":"PL03.07 hypofractionated vs conventional fractionated radiotherapy with concurrent chemotherapy for LS-SCLC: a multi-center phase III trial","volume":"20","author":"Bi","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15510","article-title":"Immune checkpoint inhibitors +\/- chemotherapy for patients with NSCLC and brain metastases: a systematic review and network meta-analysis","volume":"16","author":"Brown","year":"2025","journal-title":"Thorac Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-335","article-title":"Adding immune checkpoint inhibitors to chemotherapy confers modest survival benefit in patients with small cell lung cancer and brain metastases: a retrospective analysis","volume":"13","author":"Zhang","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B44","first-page":"1","article-title":"Chapter one - radio-induced lymphopenia in the era of anti-cancer immunotherapy","volume-title":"International Review of Cell and Molecular Biology","author":"de Kermenguy","year":"2023"},{"key":"B45","doi-asserted-by":"publisher","first-page":"S2335","DOI":"10.1016\/j.jtho.2017.09.1785","article-title":"P3.14-012 risk of developing pneumonitis increases in patients receiving immunotherapy with a history of lung irradiation","volume":"12","author":"Barron","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.06.009","article-title":"Design and rationale for a phase II\/III, randomized, double-blind, placebo-controlled study of sugemalimab as consolidation therapy in patients with limited-stage small-cell lung cancer who have not progressed following concurrent or sequential chemoradiotherapy: the SURPASS study","volume":"24","author":"Zhao","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.04.005","article-title":"Rationale and design of the phase 3 KEYLYNK-013 study of pembrolizumab with concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for limited-stage small-cell lung cancer","volume":"23","author":"Rimner","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.033","article-title":"OA04.03 ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): interim analysis of Ideate-lung01","volume":"19","author":"Rudin","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.jtho.2025.09.046","article-title":"OA06.01 a first-in-human phase 1 study of SHR-4849 (IDE849), a DLL3-directed antibody-drug conjugate, in relapsed SCLC","volume":"20","author":"Cheng","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.105","article-title":"Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6)\u2013targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms","volume":"43","author":"Cooper","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1731036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:53:20Z","timestamp":1784699600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1731036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2026.1731036"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1731036","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1731036"}}